REGiMMUNE Announces Appointments to Scientific Advisory Board
Tokyo, Japan, – Sept. 20, 2006 – REGiMMUNE Corporation announced today the appointment of Dr. Yasuyuki ISHII, Team Leader of the Laboratory for Vaccine Design at the RIKEN Research Center for Allergy and Immunology (RCAI), “We are delighted to have a world-renowned researcher with expertise in immunology and molecular biology providing us with advice to strengthen REGiMMUNE’s [...]
Completed Seed Round Financing
Tokyo, Japan – Sept. 1, 2006 – REGiMMUNE Corporation has relocated its headquarters from Toranomon, Tokyo to: 3-12-5 Shibaura, Ishizaka Bldg. 6F Minato-ku, Tokyo 108-0023 Japan phone +81-3-3456-0820
Completed Seed Round Financing
Tokyo, Japan –Aug. 15, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced the closing of the Company’s Seed Round Financing, adding $1.6 million in additional new equity. New venture capital investors NIF SMBC Ventures, Nikko AntFactory and Japan Asia Investment Company, joined existing shareholders.